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Abstract
Background: Short-acting B 2 -adrenergic receptor agonists (SABAs) are the most commonly prescribed asthma medications worldwide. Response to SABAs is measured as bronchodilator drug response (BDR), which varies among racial/ethnic groups in the U.S 1, 2 . However, the genetic variation that contributes to BDR is largely undefined in African Americans with asthma 3 .
Objective: To identify genetic variants that may contribute to differences in BDR in African Americans with asthma.
Methods: We performed a genome-wide association study of BDR in 949 African American children with asthma, genotyped with the Axiom World Array 4 (Affymetrix, Santa Clara, CA) followed by imputation using 1000 Genomes phase 3 genotypes. We used linear regression models adjusting for age, sex, body mass index and genetic ancestry to test for an association between BDR and genotype at single nucleotide polymorphisms (SNPs). To increase power and distinguish between shared vs. population-specific associations with BDR in children with asthma, we performed a meta-analysis across 949 African Americans and 1,830 Latinos (Total=2,779). Lastly, we performed genome-wide admixture mapping to identify regions whereby local African or European ancestry is associated with BDR in African Americans. Two additional populations of 416 Latinos and 1,325 African Americans were used to replicate significant associations.
Results:
We identified a population-specific association with an intergenic SNP on chromosome 9q21 that was significantly associated with BDR (rs73650726, p=7.69x10 -9 ). A trans-ethnic meta-analysis across African Americans and Latinos identified three additional SNPs within the intron of PRKG1 that were significantly associated with BDR (rs7903366, rs7070958, and rs7081864, p≤5x10 -8 ).
Conclusions: Our findings indicate that both population specific and shared genetic variation contributes to differences in BDR in minority children with asthma, and that the genetic underpinnings of BDR may differ between racial/ethnic groups.
Key messages:
-A GWAS for BDR in African American children with asthma identified an intergenic population specific variant at 9q21 to be associated with increased bronchodilator drug response (BDR).
-A meta-analysis of GWAS across African Americans and Latinos identified shared genetic variants at 10q21 in the intron of PRKG1 to be associated with differences in BDR.
-Further genetic studies need to be performed in diverse populations to identify the full set of genetic variants that contribute to BDR. 
INTRODUCTION
Albuterol, a short-acting β 2 -adrenergic receptor agonist (SABA), is the most commonly prescribed asthma medication worldwide 4, 5 . SABAs cause rapid smooth muscle relaxation of the airways. Bronchodilator drug response (BDR) is a measure of a patient's clinical response to SABA treatment and is quantitatively assessed as a change in forced expiratory volume in one second (FEV 1 ) after administration of a SABA. BDR is a complex trait involving interactions among inflammatory cells 6 , airway epithelium 7 , smooth muscle cells 8 , and the autonomic nervous system 9 . Variation in BDR is likely influenced by both population-specific and shared environmental and genetic factors [10] [11] [12] . In the United States (U.S.), BDR in children with asthma differs significantly between racial/ethnic groups 2, 10 . Specifically, African Americans have lower BDR compared to European populations even after controlling for asthma severity 13 .
Compared to European Americans, African Americans suffer increased asthma morbidity and mortality 2, 11, 14 and decreased BDR likely contributes to these disparities in disease progression and outcomes. The extensive use of albuterol as a first-line therapy for asthma, coupled with the decreased drug response (BDR) and increased disease burden in African Americans underscores the importance of identifying genetic factors that influence BDR in African American children with asthma. Once identified, these factors may lead to the generation of novel therapies and targeted interventions that will serve to improve patient care and asthma outcomes in an overburdened and under-studied population.
To date, knowledge of genetic variation that contributes to BDR in African Americans is limited to a single genome-wide association study (GWAS) in 328 individuals 3 . Previous GWAS and candidate gene studies performed in populations of predominantly European ancestry with asthma have identified several BDR candidate genes 12, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . A recent study in Latinos with asthma replicated a number of these findings, and also identified novel population-specific associations with BDR 10 . Genetic effects identified in one population are not always generalizable across populations and several population-specific asthma-risk variants have been discovered in African-descent populations (i.e. African Americans and Latinos) [25] [26] [27] .
Additionally, previous studies have shown that the varying degrees of African and European ancestry present in the African American population can be leveraged, through a technique known as admixture mapping, to identify the missing heritability of complex traits 28 . Admixture mapping is a genome-wide approach that uses the variable allele frequencies of multiple SNPs between different ancestral populations to test for an association between local ancestry and phenotype 23, [25] [26] [27] . The likelihood of population-specific effects, the limited number, and scale, of prior studies of BDR performed in African Americans, and ability to perform admixture mapping analysis highlights the possibility of gaining novel information through evaluating the impact of common genetic factors on BDR in African American children with asthma.
In this study, we performed a GWAS and admixture mapping study of bronchodilator drug response in 949 African American children with asthma from the Study of African Americans, Asthma, Genes & Environments (SAGE I and II) 29 . To increase power and distinguish between population-specific vs. shared associations, we also performed a trans-ethnic meta-analysis across our SAGE I and SAGE II participants and 1840 Latinos from GALA II (Genes-environments and Admixture in Latino Americans) studies 26 , respectively (total N=2,789). We further attempted replication of our population-specific and trans-ethnic metaanalysis results in 416 Latinos from the Genetics of Asthma in Latino Americans study (GALA I) 11, 30 and 1,325 African Americans from the Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity (SAPPHIRE) 30, 31 .
METHODS

Study subjects from the Study of African Americans, Asthma, Genes & Environments
The Study of African Americans, Asthma, Genes & Environments (SAGE) is an ongoing case-control study of asthma in children and adolescents recruited from the San Francisco Bay Institutional review boards approved the study and all subjects/parents provided written assent/consent, respectively.
Genotyping and quality control (SAGE)
A total of 1,819 samples (1,011 asthma cases and 810 controls) were genotyped with the Axiom® World Array 4 (Affymetrix, Santa Clara, CA) at ~800,000 SNPs. Quality control was performed by removing SNPs that failed manufacturer's quality control, had genotyping call rates below 95%, and/or had a deviation from Hardy-Weinberg equilibrium (p<10 -6 ) within controls. 772,135 genotyped SNPs passed quality control. Samples were filtered based on discrepancy between genetic sex and reported gender and cryptic relatedness (PI_HAT>0.3). We excluded 3 subjects who were outliers for BDR (BDR of >60, or <-10). After sample quality control we included 759 SAGE II and 190 SAGE I asthma cases, for a total of 949 individuals with both genome-wide SNP data and measurements of bronchodilator drug response in the current study (Table 1) . 
SAGE
Study subjects from the Genes-environments & Admixture in Latino Americans study
A total of 1,830 Mexican and Puerto Rican asthma cases genotyped with the Axiom LAT1 array (World Array 4, Affymetrix) for the Genes-environments and Admixture in Latino Americans (GALA II) study were included in our analysis ( Table 1 above) . Specific details about the study are described elsewhere 10 . Briefly, imputation procedures identical to those described above for SAGE I and SAGE II were implemented, resulting in a total of 7,498,942 genotyped and imputed (info score >0.3) SNPs with a MAF>0.05.
Study subjects from the Genetics of Asthma in Latino Americans study
For our replication phase, 247 Mexican and 169 Puerto Rican asthma cases genotyped with the Genome-Wide Human SNP Array 6.0 (Affymetrix) for the Genetics of Asthma in Latino Americans (GALA I) study were included. Details of the study are described elsewhere 11, 30 .
Study subjects from the Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity
For additional replication, we included 1,325 Africans Americans with asthma from the
Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity
(SAPPHIRE) genotyped with the Genome-Wide Human SNP Array 6.0 (Affymetrix). Estimates of local ancestry were obtained using RFMix 37 . Details of the study are described elsewhere 25, 31 .
Assessment of genetic ancestry
Genotypes from two populations were used to represent the ancestral haplotypes of 
Genotype association testing
All statistical analyses were conducted using R (version 2.15.3). For SAGE individuals, we used standard linear regression to test for an association between BDR and allele dosage at each individual SNP, adjusting for age, sex, BMI category, and both global and local African ancestry. A GWAS of BDR in GALA II has been previously published 10 , however, this previous work did not include adjustment for BMI; in this study we re-ran the GWAS using a new reference imputation panel and further adjusted by BMI 40 . For GALA II individuals, we adjusted for age, sex, BMI category, ethnicity, global Native American and African ancestry, and local ancestry. All analyses were performed using imputed genotypes from 1000 Genomes phase III.
Using the fixed-effects model implemented in METAL 41 , we performed a meta-analysis of common variants (MAF ≥ 5%) across African Americans (SAGE I and SAGE II) and Latinos (GALA II). We selected variants that were common (MAF ≥ 5%) within each individual study and then took the intersection of SNPs for the meta-analysis.
Admixture mapping
We used local ancestry estimates generated across the genome to perform admixture mapping in African Americans. Linear regression models adjusted for age, sex, BMI category, and global African ancestry were used to identify significant associations between local ancestry estimates and BDR. The threshold for genome-wide significance was calculated using the empirical autoregression framework with the package coda in R to estimate the total number of ancestral blocks 42, 43 . The Bonferroni threshold was calculated as α=2.4x10 -4 based on 245 ancestral blocks. Admixture mapping was performed separately in SAGE I and SAGE II and combined in a meta-analysis using METAL 41 .
Replication in GALA I and SAPPHIRE
We attempted replication of significant population-specific (SAGE I and SAGE II) and cosmopolitan (SAGE I, SAGE II, GALA II) associations with BDR in the GALA I and SAPPHIRE studies. Replication in GALA I was performed using genotype imputation (i.e. in silico replication), followed by an examination at a locus-wide level for SNPs within +/-50 kb.
We imputed 100 kb regions around each SNP using the program IMPUTE2 for Mexican and Puerto Rican participants run separately using 1000 Genomes phase 3 haplotypes as a reference.
Linear regression was used to test for an association between allele dosage and BDR separately
in Mexicans and Puerto Ricans, adjusting for age, sex, BMI category, global and local ancestry.
Replication in SAPPHIRE was also performed using linear regression to test for an association between allele dosage and BDR in African Americans while adjusting for age, sex, BMI category, and global and local African ancestry. For GALA I and SAPPHIRE replication, statistical significance at the SNP level was evaluated at p<0.05, and at the locus-wide level was established using a conservative Bonferroni correction adjusting by the number of SNPs within +/-50 kb of the original candidate SNP.
RESULTS
Genome-wide association results
After filtering variants with a MAF ≥ 5% and with imputation quality score (info score) ≥ 0.3, we tested for an association of BDR at a total of 9,190,349 SNPs in 949 African Americans with asthma (λ = 1.006). We identified a single genome-wide significantly associated SNP within an intergenic region on chromosome 9 (rs73650726, imputation quality score=0.86) (Figures 1, 2 , 3, and The SNP rs73650726 is common in African Americans but rare in Latinos, with a minor allele frequency of 8% in both SAGE studies, but at a frequency of 1% in GALA II (Table III below) . This is consistent with allele frequencies observed in the 1000 Genomes Project, where the variant is common in African populations (8%), rare in Latino populations (1-2%), and absent in European and Asian populations (Figure 4 below) 44 .
African Americans (SAGE I and II):
Chr In order to increase power and identify associations shared between populations we performed a trans-ethnic meta-analysis across African American, Mexican, and Puerto Rican participants from SAGE I, SAGE II, and GALA II, respectively. Following quality control and filtering on variants common in each study (MAF ≥ 5%), we took the overlap between the three studies and we performed a meta-analysis on 6,570,864 SNPs (λ = 1.004). We identified genome-wide significant associations at three SNPs located on chromosome 10 within the intron Tables II & III above). All three SNPs are eQTLs for PRKG1 in lung tissue from the GTEx database (Table IV below) 45 , with the minor allele associated with decreased expression. Replication of African American population-specific (rs73650726) and shared (rs7903366, rs7070958, rs7081864) was attempted in two independent Latino (GALA I) and
SNP
African American (SAPPHIRE) studies. Although none of the identified associations replicated in either study population, the African American population-specific association between rs73650726 and BDR, identified in the SAGE studies, displayed a similar trend in direction of effect in Puerto Ricans (GALA I; β = -6.2) and in African Americans (SAPPHIRE, β = -0.65) ( 
Admixture mapping results
We tested for an association of BDR with local genetic ancestry inferred at 478,441 SNPs in 949
African Americans with asthma (190 from SAGE I and 759 from SAGE II) (Figures 8 & 9 below). A meta-analysis across both studies yielded no significant associations with ancestry (p< 2.4x10 -4 ) (Figure 10 below). The most significant peak was located on chromosome 8p11 where African ancestry was associated with higher BDR (β=1.49, p=6.34x10 -4 ) ( Table VIII below 
DISCUSSION
We performed a genome-wide association study for bronchodilator drug response in African Americans, and identified a population-specific association between rs73650726, located on chromosome 9, and BDR. Specifically, we discovered that the G allele of rs73650726 was associated with increased BDR and is more common in African Americans compared to European populations (Table II above) . The variant rs73650726, located on chromosome 9, does not map to any gene, but SNPs in high linkage disequilibrium (r 2 ≥0.8) with this marker are located in enhancer histone marks in lung tissues 46 . Our results demonstrate that population-specific genetic variation contributes to variation in BDR in African American children with asthma. We further combined our results in a metaanalysis for BDR in African Americans and Latinos and identified multiple intronic variants in PRKG1 that were associated with BDR in both populations. Overall our results demonstrate that population-specific and shared genetic factors contribute to variation in BDR among African American children with asthma. Through investigating the underlying genetics of BDR in diverse populations we have uncovered novel information regarding both the pathophysiology and pharmacogenetics of asthma.
Three of our significantly associated variants fell within the intronic region of an annotated gene, Protein Kinase, CGMP-Dependent, Type I (PRKG1). PRKG1 encodes for a cyclic GMP-dependent protein kinase, which phosphorylates proteins involved in regulating platelet activation and adhesion 47 , gene expression 48, 49 , vascular smooth muscle cell contraction 50 , and feedback of the nitric-oxide (NO) signaling pathway 51 . Notably, the NO pathway is a key pathway in modulating vasodilation in response to beta-agonists such as albuterol via beta 2-adrenergic receptors 52 , making PRKG1 a highly plausible BDR candidate gene. The three SNPs are in high linkage disequilibrium (r 2 ≥0.8) with variants known to be functional 46 , and are all associated with the expression of PRKG1 in the lung -a tissue highly relevant to BDR. From the Genotype-Tissue Expression (GTEx) project database, the reference allele for all three SNPs was associated with decreased expression of the gene in lung tissue 45 .
Thus, additional studies are required to identify the causal underlying variation at this locus, such as direct sequencing of this locus, and how the expression of PRKG1 may be related to differences in BDR.
associated with BDR, however we found no significant associations following multiple testing corrections. This could be due to differences in study design, the presence of population specific differences in genetic contributions to BDR, and/or varying patterns of linkage disequilibrium between populations. Furthermore, we were limited in sample size in GALA I 25 to evaluate associations at low frequency variants, and note that SAPPHIRE is comprised of mainly adults 31 in comparison to SAGE and GALA II that are comprised of mainly children.
In conclusion, we identified two novel loci with biological plausibility whereby genetic variation is associated with differential response to albuterol, the most commonly prescribed asthma medication. One of these loci contains variation associated with BDR that is common to African Americans, a population that has historically been understudied in genetic studies [53] [54] [55] .
Further genetic studies in African Americans is essential for identifying a more comprehensive set of genetic variants that contribute to differences in BDR, which in turn will lead to a better understanding of the pharmacogenetic response to asthma therapies. This will provide the foundation for genetic risk profiling and precision medicine, identifying novel genes and pathways associated with BDR, and the development of novel asthma therapies.
